Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.

Keller SF, Kelly JL, Sensenig E, Andreozzi J, Oliva J, Rich L, Constine L, Becker M, Phillips G, Liesveld J, Fisher RI, Bernstein SH, Friedberg JW.

Biol Blood Marrow Transplant. 2012 Apr;18(4):640-7. doi: 10.1016/j.bbmt.2011.08.012. Epub 2011 Aug 24.

2.

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.

Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ.

Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72.

3.

Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.

Sibon D, Ertault M, Al Nawakil C, de Bazelaire C, Franchi P, Brière J, de Kerviler E, Beranger N, Thieblemont C, Brice P.

Br J Haematol. 2011 Apr;153(2):191-8. doi: 10.1111/j.1365-2141.2011.08594.x. Epub 2011 Mar 8.

PMID:
21385169
4.
5.
6.

[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].

Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.

Harefuah. 2000 Sep;139(5-6):174-9, 248, 247. Hebrew.

PMID:
11062945
7.

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A.

Ann Oncol. 2008 Jul;19(7):1312-9. doi: 10.1093/annonc/mdn052. Epub 2008 Mar 19.

PMID:
18356139
8.

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi.

N Engl J Med. 2011 Jul 21;365(3):203-12. doi: 10.1056/NEJMoa1100340.

9.

High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma.

Di Ianni M, Ballanti S, Iodice G, Reale A, Falzetti F, Minelli O, Serio G, Martelli MF, Dammacco F, Vacca A, Ria R.

Hematology. 2012 Jan;17(1):23-7. doi: 10.1179/102453312X13221316477534.

PMID:
22549444
10.

Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.

Enrici RM, Anselmo AP, Donato V, Falchetto Osti M, Santoro M, Tombolini V, Mandelli F.

Haematologica. 1999 Oct;84(10):917-23.

11.

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.

Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ.

Blood. 2005 Aug 15;106(4):1473-8. Epub 2005 May 3.

13.

Standard therapy of advanced Hodgkin lymphoma.

Kuruvilla J.

Hematology Am Soc Hematol Educ Program. 2009:497-506. doi: 10.1182/asheducation-2009.1.497. Review.

PMID:
20008235
14.

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.

Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE; National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group.

J Clin Oncol. 2005 Jul 20;23(21):4634-42. Epub 2005 Apr 18.

PMID:
15837968
15.

Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.

Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, López-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H; GESIDA Group; GELCAB Group.

Haematologica. 2007 Feb;92(2):191-8.

16.

Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.

Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.

Bone Marrow Transplant. 2000 Aug;26(4):383-8.

17.

Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.

Karmiris TD, Grigoriou E, Tsantekidou M, Spanou E, Mihalakeas H, Baltadakis J, Apostolidis J, Pagoni M, Karakasis D, Bakiri M, Mitsouli C, Harhalakis N, Nikiforakis E.

Leuk Lymphoma. 2003 Sep;44(9):1523-8.

PMID:
14565654
18.
19.

Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.

Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Oliveira JS.

Ann Hematol. 2009 Jul;88(7):633-7. doi: 10.1007/s00277-008-0635-0. Epub 2008 Nov 8.

PMID:
18998131
20.

Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation.

Fernández de Larrea C, Martínez C, Gaya A, López-Guillermo A, Rovira M, Fernández-Avilés F, Lozano M, Bosch F, Esteve J, Nomdedeu B, Montserrat E, Carreras E.

Ann Oncol. 2010 Jun;21(6):1211-6. doi: 10.1093/annonc/mdp487. Epub 2009 Nov 4.

PMID:
19889622

Supplemental Content

Support Center